Form 4: Collegium Pharmaceutical Director John A. Fallon Acquires Shares Through Restricted Stock Units

Director John A. Fallon of Collegium Pharmaceutical, Inc. reports acquisition of shares through restricted stock units.

Summary

• On May 15, 2025, John A. Fallon, a director of Collegium Pharmaceutical, Inc., acquired 9,791 shares of common stock through the grant of restricted stock units (RSUs).
• Each RSU represents a contingent right to receive one share of Collegium Pharmaceutical's common stock.
• The RSUs vest on the earlier of May 15, 2026, or the date of the Issuer's 2026 Annual Meeting of Shareholders, contingent upon the director's continued service.
• Following the transaction, Fallon beneficially owns 64,634 shares of Collegium Pharmaceutical common stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it's a standard disclosure of stock acquisition by a director. It doesn't inherently indicate positive or negative sentiment, but rather provides information about insider activity.

Positives

• The acquisition of shares by a director can be seen as a positive sign, indicating confidence in the company's future prospects.

Future Outlook

The RSUs will be settled on the vesting date, or earlier upon certain events such as the end of the director's service, death, disability, or a change in control of the Issuer, in shares of the Issuer's common stock.

Industry Context

This filing is a routine disclosure of insider transactions, which are common in publicly traded companies. It provides transparency into the actions of company insiders.

Stakeholder Impact

• The transaction could have a minor positive impact on shareholders if it signals confidence from a company director.

Key Dates

Keywords

Collegium Pharmaceutical, Director, John A. Fallon, Restricted Stock Units, RSUs, Beneficial Ownership, Form 4, SEC Filing